Lupin Ltd

These Two Stocks To Be Added Into Sensex

Business | Thomson Reuters | Friday November 17, 2017

Drugmakers Lupin Ltd and Cipla Ltd will make way for the two banks, according to a statement from Asia Index Pvt Ltd.

Lupin Founder And Chairman Desh Bandhu Gupta Dies

Business | NDTV Profit Team | Monday June 26, 2017

Desh Bandhu Gupta, founder and chairman of pharmaceuticals company Lupin Ltd, died early morning on Monday in Mumbai.

Lupin Gets USFDA Nod To Market Cancer Drug

Business | Press Trust of India | Tuesday February 28, 2017

Pharma major Lupin Ltd has received final approval from the USFDA to market sodium sulfate, potassium sulfate, magnesium sulfate oral solution used in treatment of a form of cancer.

Lupin Launches Voriconazole Tablets For Treatment Of Fungal Infectinos

Business | Press Trust of India | Monday December 19, 2016

Homegrown pharma major Lupin Ltd on Monday announced the launch of generic version of its voriconazole tablets and oral suspension used for treatment of fungal infectinos in children.

Sensex Heads For Second Straight Fall; Lupin Drags

Business | Reuters | Wednesday August 10, 2016

Indian shares fell on Wednesday and were headed for their second straight session of declines, as drug maker Lupin Ltd dropped on concerns about its earnings outlook and as investors weighed whether the recent rally in equities may have been overdone.

Lupin Q1 Profit Jumps 55%, Gets Boost From Lower Tax Rate

Business | Reuters | Tuesday August 9, 2016

Lupin Ltd, India's third largest drug maker, posted a 55 per cent rise in quarterly profit, but shares fell as some analysts noted the jump was driven in part by a lower tax rate.

Lupin To Buy 21 Branded Drugs From Japan's Shionogi

Business | Reuters | Tuesday August 2, 2016

Indian drugmaker Lupin Ltd said it had agreed to buy a portfolio of 21 drugs from Japan's Shionogi & Co Ltd for 15.4 billion yen ($150 million), expanding its presence in its third-largest market.

Lupin Q2 Profit Lags Estimates on Fewer Drug Launches

Business | Thomson Reuters | Tuesday October 27, 2015

Lupin Ltd, India's third largest drug maker by sales, hopes to win approvals for some key products in its largest market, the United States, by the end of this year, after fewer product launches pushed second-quarter profit below estimates.

Lupin Launches Hyperphosphatemia Treatment Capsules in US

Business | Press Trust of India | Monday October 26, 2015

Lupin has launched calcium acetate capsules, used in treating hyperphosphatemia in end stage renal failure, in the United States after receiving approval from the US Food and Drug Administration (FDA).

FIPB Clears FDI Proposals of Lupin, Alkem Lab: Report

Business | Press Trust of India | Monday October 19, 2015

The government today cleared 14 foreign investment proposals, including that of Lupin Ltd and Alkem Laboratories Ltd.

Lupin Looks to Revive US Growth With $880-Million GAVIS Deal

Business | Thomson Reuters | Thursday July 23, 2015

Lupin Ltd, India's third-largest drug maker by sales, is buying US peer GAVIS Pharmaceuticals LLC for $880 million (Rs 5,588 crore at $1 = Rs 63.5) in its largest ever acquisition, seeking to revive its flagging growth in the United States, its largest market.

Lupin Acquires Russian Drug Firm Biocom

Business | Press Trust of India | Thursday July 2, 2015

The company has acquired 100 per cent equity stake in ZAO Biocom in Russia subject to certain closing conditions, Lupin Ltd said in a statement without disclosing the financial details.

RBI Allows FIIs to Invest Upto 49% of Paid Up Capital in Lupin

Business | Press Trust of India | Thursday February 12, 2015

The Reserve Bank today said foreign institutional investors and registered foreign portfolios investors can now invest up to 49 per cent of the paid-up capital in Lupin Ltd under Portfolio Investment Scheme (PIS).

Lupin Gets USFDA Approval for Diarrhoea Drug

Business | Monday February 2, 2015

The company has received final approval for its Vancomycin Hydrochloride Capsules in strengths of 125 mg and 250 mg from the US Food and Drugs Administration (FDA) to market a generic version of ANI Pharmaceuticals, Inc's Vancocin, Lupin Ltd said in a statement.

Court Order Restraining Drug Sale Disappointing: Cipla

Business | Saturday January 10, 2015

Cipla has expressed disappointment over a Delhi High Court order restraining the drug maker from manufacturing and selling any medicine containing 'Indacaterol', saying that the interim verdict would deny patients access to the drugs they need.